[ad_1]
German scientists say they have broken the cause of the rare blood clots associated with the Oxford / AstraZeneca and Johnson & Johnson coronavirus vaccines and believe the blows can be adapted to make the reaction complete.
Rolf Marschal, a professor at Goethe University in Frankfurt who has been conducting research on the rare state since March, said his research has shown that the problem lies with the adenobirus vectors used by both vaccines to deliver spicy Sars-Cov-2 protein. virus in the body.
The delivery mechanism means that vaccines send the vertebral protein to the cell nucleus rather than the liquid cytosol found inside the cell that normally produces the protein, said Marschal and other scientists. preprint paper released on Wednesday.
Entered into the cell nucleus, some fragments of the granular protein are broken down or fragmented, creating mutant versions that cannot be bound to the cell membrane where significant immunization occurs. According to Marschal’s theory, floating mutant proteins are secreted by cells into the body, causing blood clots in approximately 100,000 people.
In contrast, mRNA-based vaccines, such as jabs developed by BioNTech / Pfizer and Moderna, transmit the genetic material of the vertex to the fluid cell and never enter the nucleus.
“When these. . . the genes of the virus in the nucleus can cause some problems, “Marschal told the Financial Times.
A rare blood clotting reaction that disrupted the spread of AstraZeneca and J&J shootings has been reported in 309 of the 33 million people who have been vaccinated with AstraZeneca in the UK and has caused 56 deaths. In Europe, at least 142 people have experienced blood clots from 16 million vaccine recipients.
In response, the use of the AstraZeneca property has been restricted or suspended in more than a dozen countries. J&J began spreading its vaccine in Europe with a warning on its label in April due to concerns after a brief delay.
But Marschal believes the correct “solution” is that vaccine developers can change the sequence of the vertex protein so that it does not separate.
J&J had already contacted Marschal’s lab to ask for guidance and to avoid splicing who was studying ways to adapt his vaccine, he said.
The J&J shot spike protein was no longer less likely to “bind” than the spike protein owned by AstraZeneca, and the reaction is less common, according to Marschalek. In the U.S., eight of the 7.4m recipients of the J&J shooting have reported a strange reaction.
“[J&J] he is now trying to optimize his vaccine, “he said.” With the data at hand, we can tell companies how to mutate these sequences by coding them in such a way as to avoid unintentionally mixed spike protein reactions. “
J&J said: “We are conducting ongoing research and analysis of this rare event while working with medical experts and global health authorities. We look forward to reviewing and sharing the data as it becomes available.”
Some scientists have warned that it is among Marschalk’s many theories, and that more evidence is needed to prove his claims.
“There is a lack of evidence to show the chain of cause of the discussion… In the lump protein for thrombosis events,” said Johannes Oldenburg, a professor of transfusion medicine at Bonn University. “It’s still a hypothesis that needs to be proven through experimental data.”
Marschal said he presented the findings of his laboratory to the Paul-Ehrlich Institute of the German government and the country’s advisory body for vaccination and vaccination.
“Our findings surprised us because no one was thinking about the link problem,” he said.
[ad_2]
Source link
